Insulet Corporation
Insulet Appoints Former JP Morgan Executive to Board
Summary
On October 23, 2025, Insulet Corporation announced the appointment of Robbie Huffines, former Global Chair of Investment Banking at JP Morgan Chase & Co., to its Board of Directors, effective October 31, 2025. Huffines, who brings over three decades of experience in healthcare investment banking, will also serve on the Audit Committee. The appointment was disclosed via a press release furnished as Exhibit 99.1.
Profitelligence Alerts
Get alerts for PODD
Be first to know when Insulet Corporation files with the SEC.
Filing Categories
Advertisement
About Insulet Corporation
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.
Official SEC Documents
Advertisement